Tag Archives: venture capital

Introducing BioVenture Voices: A New Segment in Next Phase 

8 Jul

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022Life Science Nation (LSN) is excited to introduce a new segment to our weekly Next Phase newsletter: BioVenture Voices, a collaborative feature powered by BioTechTV. This series highlights the personal stories, lessons, and perspectives of founders, investors, and industry leaders driving early-stage innovation across biotech, medtech, diagnostics, and digital health.

BioVenture Voices captures candid interviews with people navigating the complex path from scientific breakthroughs to market-ready products. Whether you’re an entrepreneur seeking capital, an investor tracking emerging trends, or a strategic partner scouting for innovation, these conversations offer unfiltered viewpoints and practical takeaways straight from those in the trenches.

In alignment with LSN’s mission to connect innovative startups with early-stage investors and partners, BioVenture Voices adds a human dimension to the investment landscape—featuring voices you might meet on the RESI partnering platform, in the Exhibition Hall, or on stage during an Innovator’s Pitch Challenge session.

Starting this week, readers can look forward to regular installments of BioVenture Voices in Next Phase, offering an up-close look at the minds behind science. Watch, listen, and learn from the stories shaping the future of healthcare innovation.

To launch the series, we’re pleased to share an interview with Bryan Roberts, Partner at Venrock, who reflects on the evolution of venture investing in biotech, what he looks for in early-stage opportunities, and how the relationship between founders and investors has changed over time.

RESI Boston Webinar Series: Your Roadmap to a Stronger Pitch, Smarter Partnering, and Greater Investor Engagement 

8 Jul

By Max Braht, Director of Business Development, LSN

Max-Braht-HeadshotRESI Boston returns September 17 to 19, 2025, and in the lead-up to the event, Life Science Nation is offering a series of free educational webinars designed to help life science startups strengthen their pitch, navigate partnering, and engage more effectively with investors. Whether you are pitching at the Innovator’s Pitch Challenge, booking one-on-one meetings, or attending RESI for the first time, these sessions offer valuable tools to get the most out of your conference experience.

July 10, 2025 at 12:00 PM
Standing Out to Investors: How to Tell Your Startup Story for Maximum Impact – Sign Up
The most successful entrepreneurs are powerful storytellers. This interactive bootcamp will show you how to shape and share your startup’s story for maximum investor impact. Learn how to sharpen your elevator pitch, refine your 12-slide deck, and make your messaging resonate with different stakeholders in the deal chain. Participants will leave with actionable language tools and techniques to boost their confidence and communication skills.


July 22, 2025 at 12:00 PM
Tips on Pitching: From the Application to the Q and A – Sign Up
Get a firsthand look at what makes a pitch resonate with investors. Join RESI judge, Bruce Cohen, who has sat on both sides of the table as an investor and an Innovator’s Pitch Challenge participant, for an inside perspective on how to stand out. This session covers best practices for your application, how to deliver a clear and convincing pitch, and how to prepare for and respond to investor Q and A.


August 7, 2025 at 12:00 PM
Biotech Exec Webinar – Who should be on your executive team? Structuring for success and fractional execs. – Sign Up
Join Life Science Nation (LSN) and Biotech Exec in early August for a free webinar on how to structure your life science startup executive team for success. Startups can fall victim to many strategic mistakes even when the science holds up. Choosing the right indication. Performing the right assay. Designing the right trial. Structuring a fund raise optimally. But one of the least talked about mistakes is putting the wrong people on the executive team or simply not brining on the right talent. We will have an engaging discussion that will include case studies of how things went wrong and testimonials from experienced CEOs and investors regarding what went right and what went wrong in their previous experience. Investors have a knack for knowing immediately if the executive team is poised to go the distance. Learn how to avoid the pitfalls most investors look for to ensure your barrier to fundraising is at a minimal. Learn if a fractional exec is right for you or if you should be looking for full-time right away.


August 18, 2025 at 12:00 PM
Partnering Tutorial: Making the Most of the RESI System – Sign Up
RESI’s partnering system is a powerful tool—but only if you know how to use it. Join the LSN team as we walk through how to navigate the platform, target the right investor fit, manage your outreach, and make the most of every meeting. We will also share our recommended strategy for follow-ups and how to leverage RESI content to support your fundraising journey.


September 4, 2025 at 12:00 PM
Investor Fireside Chat: Fundraising in Today’s Biotech Climate – Sign Up
Hear directly from investors about what is driving deal flow in the life science ecosystem. This fireside chat will cover current investment trends, what investors are looking for in early-stage biotech companies, and how startups can better position themselves to raise capital. Bring your questions and gain insight from experts who know what makes a company fundable.

Registration is open for all webinars. These sessions are free to attend and are designed to help you prepare for meaningful investor interactions and set yourself up for success at RESI Boston this September.

New Aging & Longevity Track Launches at RESI Boston via Partnership Between Longevity Global and Life Science Nation 

1 Jul

By Matt Stanton, VP Sales US West, Central and South America, LSN

Longevity Global (LG) and Life Science Nation (LSN) are proud to announce a new partnership to launch a dedicated Aging & Longevity Track at the upcoming RESI (Redefining Every Stage of Investments) Boston Conference this September. This collaboration brings together two leading organizations committed to advancing innovation in healthcare and biotech, positioning longevity-focused startups at the center of global investor and partner engagement.

The Aging & Longevity Track will serve as a curated platform for Longevity Global’s community of founders, researchers, and entrepreneurs to connect with LSN’s expansive partnering ecosystem, including global capital investors and licensing partners. Participating companies will gain access to panels, workshops, educational sessions, and networking opportunities tailored to early-stage ventures across the healthcare spectrum. Longevity Global attendees will also have the option to upgrade to RESI’s renowned one-on-one partnering platform, which allows them to connect directly with strategic partners and capital sources.

“This collaboration gives our longevity ecosystem direct access to global capital and strategic relationships that can accelerate the path from research to real-world impact,” said Christin Glorioso, Founder and CEO at Longevity Global. “The opportunity to plug into RESI’s cross-sector audience while bringing aging science to the forefront is a huge step forward for our mission.”

LSN also views this partnership as a powerful gateway to expand its reach within the rapidly growing longevity sector. “Longevity is one of the most promising frontiers in healthcare, and we’re excited to help emerging companies in this space connect with the capital and partners they need to scale,” said Dennis Ford, CEO of Life Science Nation. “Partnering with Longevity Global allows us to provide a highly curated experience that meets the needs of this evolving vertical.”


About Longevity Global
Longevity Global is a mission-driven community and event platform that connects scientists, startups, and investors working to solve aging. As a branch of Academics for the Future of Science, a 501(c)(3) nonprofit, LG curates events and programs across San Francisco, New York, Boston, the UAE, and beyond.


About Life Science Nation & RESI
Life Science Nation (LSN) is a global partnering platform for every stage of life science companies, offering a suite of tools that includes a database of over 6,000 investors, RESI partnering conferences, and commercialization support. RESI events connect startups with investors and strategic partners across drugs, devices, diagnostics, and digital health.

For more information about RESI Boston September 2025 conferences, contact us at resi@lifesciencenation.com.

Investor Panels at RESI Boston September

24 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

RESI Boston returns on September 17, 2025 at the Westin Copley Place, once again serving as a core event during Biotech Week Boston. Organized by Life Science Nation, RESI (Redefining Every Stage of Investment) brings together life science and healthcare companies with hundreds of investors and strategic partners for a day of partnering, networking, educational content, and exhibits.

A highlight of every RESI conference is the investor panel programming, where active investors and strategics speak directly to entrepreneurs about what they’re looking for, how they invest, and how startups can position themselves for success. The upcoming September event will feature deep dives into some of the most dynamic areas of healthcare innovation, featuring speakers from impact investors, corporate venture arms, Big Pharma, family offices, and more.

Impact Investors & Venture Philanthropy Panel

The Role of Impact Investing in the Healthcare Ecosystem

Impact investors and venture philanthropists are playing a growing role in backing early-stage healthcare ventures, especially those addressing health equity and underserved areas. In this panel, leaders in the field will discuss how they define and measure impact, what they look for in mission-driven ventures, and how they work with founders to align values with milestone-based progress. Attendees will gain insight into how this capital is deployed to catalyze innovations that go beyond traditional ROI.


Mental & Behavioral Health Panel

Investing in Solutions for Higher Quality of Life and Wellbeing

With 1 in 8 people globally affected by mental disorders, demand for novel solutions in behavioral health continues to grow. This panel features investors who are actively backing companies developing digital tools, neurotechnologies, care delivery innovations, and novel therapeutics. Panelists will explore challenges such as stigma, reimbursement, and regulation—along with what it takes for startups to stand out in this vital and rapidly evolving market.


Oncology Innovation Panel

Latest Scientific Breakthroughs and Future Outlook

Oncology continues to attract robust investor interest, yet the bar for scientific rigor and differentiation is high. This session gathers investors focused on oncology diagnostics, therapeutics, and platforms to discuss what excites them in the current landscape and what it takes to succeed. Topics include scientific novelty, clinical de-risking, commercial potential, and where the next wave of oncology innovation may arise.


Corporate VC Panel

Venture and Innovation Arms Making Strategic Investments

Corporate VCs offer much more than capital, they bring strategic alignment, deep expertise, and long-term partnership opportunities. In this session, leaders from CVC arms of major pharma, biotech, and medtech companies will discuss how they source and evaluate early-stage deals, what startups should expect post-investment, and how founders can navigate alignment with a corporate parent. This panel is essential for startups seeking strategic investors.


Diagnostics Panel

Investing in Innovations for Preventative and Personalized Care

As diagnostics become increasingly central to precision medicine and population health, investors are paying close attention. Panelists in this session will discuss how they evaluate new diagnostic technologies, from regulatory and reimbursement outlooks to commercial differentiation and unmet need. For entrepreneurs developing platforms in oncology, infectious disease, or chronic conditions, this discussion will provide actionable guidance on positioning and funding strategies.


Partnering with Big Pharma Panel

What Startups Need to Know to Get on Big Pharma’s Radar

Securing a partnership with Big Pharma can be a transformative milestone. This panel features business development and venture leaders from leading pharmaceutical companies who will share what they look for in early-stage collaborations. Learn how they assess risk, stage readiness, and strategic fit—plus how startups can build compelling cases for co-development, licensing, or investment.


Family Offices Panel

Perspectives on Early-Stage Investments

Family offices have become increasingly visible in early-stage healthcare deals, often offering patient capital and values-driven investment strategies. This panel will unpack how these investors approach opportunity evaluation, what sets them apart from traditional VCs, and how they support portfolio companies beyond capital. Attendees will also hear practical advice for engaging family offices and building meaningful relationships.


Whether you’re developing breakthrough diagnostics, therapeutics, platforms, or care delivery solutions, the RESI Boston investor panels offer a unique opportunity to hear directly from the funders shaping the future of healthcare.

Interested in sharing your insights at RESI? Reach out to join our speaker lineup!

Register by July 11 to lock in Super Early Bird Rates and save $300. Secure your spot today and join 400+ investors and strategic partners this September in Boston.

Introducing BD Assist: LSN Sets Up the Meetings For Your Global Investor Roadshow

24 Jun

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022Life Science Nation (LSN) pioneered investor engagement through its RESI Conferences, global investor database, and entrepreneurial education programs. LSN is taking a significant leap forward with the launch of BD Assist, a full-service investor outreach and meeting management product designed to augment and complement your in-house BD efforts.

With BD Assist, LSN aids in the tedious task of booking meetings with your partner targets:

  • LSN Labs AI Agent will optimize your messaging for outreach.
  • Identify and prioritize well-matched capital and licensing partners
  • Conduct coordinated outreach
  • Schedule and confirm investor meetings on your behalf

The product development, regulatory, and operational complexities of running a life science company are already challenging enough. BD Assist removes one of the most tedious but significant burdens: finding, securing, and managing investor meetings.

Why LSN Is Uniquely Positioned to Do This
LSN combines getting the right target list, a proven canvassing and follow-up methodology, and a dedicated outreach team to deliver results. LSN is a well-known, trusted, and credible entity in the partnering space. We know what life science investors are looking for and which meetings they’ll take. Over the past decade, we’ve taught hundreds of startups how to craft their story, manage outreach, and execute CRM-powered campaigns. The results are real; see our Australian accelerator cohort, where 90% of companies secured funding or strategic partnerships.

BD Assist takes on the daily work of driving your campaign forward. We handle the outreach, schedule your meetings, manage follow-up, and sync it all to your CRM in real time. You stay focused on the science, and we set up the business development meetings. If you’re raising capital or licensing in the next 12 months, BD Assist is your opportunity to launch a turnkey global campaign without hiring a whole BD team.

Ready to activate your global roadshow?
Contact us at salescore@lifesciencenation.com to get started.

The RESI Boston June 2025 Program Guide Release

10 Jun

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022The official program guide for RESI Boston, June 2025 is now available! Redefining Every Stage of Investment (RESI) is built to connect life science and healthcare innovators with a global network of investors representing a wide range of funding strategies, from Seed through Series B and beyond.

This guide provides an overview of what to expect throughout the conference, detailing all of the content and layout for our in-person event on June 16th. Inside, you’ll find the full agenda, speaker bios, panel descriptions, and key information to help you navigate your RESI experience. Whether you’re participating in investor meetings, pitch sessions, workshops, or ad hoc networking, this guide is your resource to stay informed and get the most out of RESI Boston.

Access the full guide here:

Introducing the Investor Judges for the Innovator’s Pitch Challenge at RESI Boston 

10 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

RESI Boston takes place on June 16, and Life Science Nation is pleased to announce the investor judges participating in this event’s Innovator’s Pitch Challenge (IPC). With more than 50 companies presenting across 14 sessions, the IPC offers life science startups a high-impact opportunity to gain visibility, pitch directly to active investors, and receive valuable feedback in real time.

Each session will feature investor and strategic partner judges with expertise spanning therapeutics, medical devices, diagnostics, digital health, and life science tools. Following every pitch, judges will lead a live Q&A to assess the opportunity and share insights from the investor perspective.

Every IPC company will also have a dedicated table in the RESI Exhibition Hall, making it easy for attendees to connect with founders and learn more.

All registered attendees will be invited to vote online for their favorite companies, and the Top 3 companies will be announced at the end of the day’s cocktail reception. Winners will receive a prize and be featured in an upcoming issue of the LSN newsletter.

Scroll down to see which investors will serve as judges for this year’s IPC:

John Abeles
John Abeles
General Partner
Northlea Partners
Chris Aleong
Chris Aleong
VP
BioIdeations
Christina Ansted
Christina Ansted
Sr. Managing Partner
RCP Venture Capital
Jit Basak
Jit Basak
Investor
Launchit Ventures
Jay Batchu
Jay Batchu
Entrepreneur in Residence
Xontogeny
Randy Berholtz
Randy Berholtz
Sr. Advisor
Mesa Verde Venture Partners
Jeff Berman
Jeff Berman
Managing Partner & Co-Founder
Big Tree Innovation Fund
Kalyan Chakravarthy
Kalyan Chakravarthy
Sr. Manager, External Innovation
Ipsen S.A.
Jo Chaturvedi-Durant
Jo Chaturvedi-Durant
Sr. Investor & Venture Partner
VU Venture Partners
Shailesh Chavan
Shailesh Chavan
Managing Partner
Transatlantic Life Science Venture
Nicolas Cindric
Nicolas Cindric
Partner
Yahara Ventures
Javier Coindreau
Javier Coindreau
General Partner (Boston)
Sila B Health Ventures
Bettina Ernst
Bettina Ernst
Director
BERNINA BioInvest
Alex Fair
Alex Fair
Managing Partner
Medstartr Capital
Dimitra Georganopoulou
Dimitra Georganopoulou
Managing Director
Qral Ventures
Serban Georgescu
Serban Georgescu
Due Diligence Chair
Mass Medical Angels
Ken Grise
Ken Grise
Principal
Sixty Degree Capital
Marco Gulla
Marco Gulla
Investment Associate
Health Technology Holding (HTH)
George Hong
George Hong
Investor
H Advisor Group
Guanghui Hu
Guanghui Hu
Venture Partner & CEO
Viva BioInnovator
Kristin King-Jankiewicz
Kristin King-Jankiewicz
Member & Head of Group Management
Boston Harbor Angels
Claire Leurent
Claire Leurent
Managing Director
AbbVie
Vivian Li
Vivian Li
SA
K2 Venture Partners
Ali Malihi
Ali Malihi
President
Back Bay Group
Nune Martiros
Nune Martiros
Sr. Associate
Paladin Capital Group
Jim McGough
Jim McGough
Managing Partner
Mid Atlantic Bio Angels
Ralph Morales III
Ralph Morales III
Venture Partner / Executive-in-Residence
Aquillius Ventures
Jose Navarro
Jose Navarro
Scientific Director & Partner
quadraScope Venture Fund
Lizzie Ngo
Lizzie Ngo
Principal
Longwood Fund
Yoichi Omae
Yoichi Omae
BD Director
Asahi Intecc USA Inc
Soyoung Park
Soyoung Park
General Partner
1004 Venture Partners
Chandra Ramanathan
Chandra Ramanathan
VP and Head of External Innovation, Life Sciences Innovation Group
Danaher Corporation
Nans Rivat
Nans Rivat
VP
PACE Healthcare Capital
Shreya Sawant
Shreya Sawant
Venture Partner
Aquillius Ventures
Pranav Seshadri
Pranav Seshadri
Investor
T.Rx Capital
Jason Shieh
Jason Shieh
Partner/Co-Founder
HelixPoint Capital
Oliver Sims
Oliver Sims
Investment Manager
Octopus Ventures
Alex Spicer
Alex Spicer
M&A Associate
SERB Pharmaceuticals
Sri Sriadibhatla
Sri Sriadibhatla
Director, Healthcare Investment Group
Ben Franklin Technology Partners of Southern Pennsylvania
Isaac Stoner
Isaac Stoner
EIR
Slater Technology Fund
Asad Taherbhoy
Asad Taherbhoy
Angel Investor
Angel Star Ventures
Wei Tao
Wei Tao
Board Director & Chair, Bio/Genomics
Life Science Angels
Vince Wong
Vince Wong
CEO and President
BioCrossroads
Chris Yoo
Chris Yoo
General Partner and Managing Director
Xcellerant Ventures
Doug Zingale
Doug Zingale
Co-Founder & Managing Partner
Blue Goose Capital
Patrick-Cooke
Patrick Cooke, PhD
Associate
Merck Digital Sciences Studio
SERB Pharmaceuticals
Samuel Freedman
M&A Analyst
SERB Pharmaceuticals